BACKGROUND: Primary angioplasty has been introduced for the treatment of symptomatic cerebral vasospasm in patients with subarachnoid hemorrhage (SAH). The data regarding the therapeutic benefit of angioplasty in improving patient outcomes are limited, hence its utilization at hospitals remains controversial and currently is not reimbursed by Medicare or major insurance companies. METHODS: We analyzed the data from Nationwide Inpatient Sample (NIS), a nationally representative dataset of all admissions in the United States from 2005 to 2007. We analyzed the prevalence of angioplasty procedure for cerebral vasospasm at the national level. In-hospital mortality, discharge status, length of stay, and cost of hospitalization were compared between hospitals performing angioplasty with those not performing angioplasty in multivariable model, adjusted for patient's age, utilization of endovascular aneurysm obliteration, and disease severity. RESULTS: Of the 74,356 estimated patients with nontraumatic SAH, 47% (n = 35,172) were admitted to hospitals that perform angioplasty for cerebral vasospasm and only 1307 patients (3.8%) were treated with angioplasty for vasospasm. In multivariable analysis, after adjustment for patient and hospital characteristics, we found that patients admitted to hospitals performing angioplasty had higher rates of discharge to home without supervision (OR 1.3, 95% CI: 1.1-1.6). There was no difference in in-hospital mortality, length of stay, or cost of hospitalization. CONCLUSIONS: Our analysis suggests that the odds of a patient being discharged to home are better at hospitals performing angioplasty for cerebral vasospasm. Provision of angioplasty may be used as a surrogate marker of model of care in management of patients with SAH.
BACKGROUND: Primary angioplasty has been introduced for the treatment of symptomatic cerebral vasospasm in patients with subarachnoid hemorrhage (SAH). The data regarding the therapeutic benefit of angioplasty in improving patient outcomes are limited, hence its utilization at hospitals remains controversial and currently is not reimbursed by Medicare or major insurance companies. METHODS: We analyzed the data from Nationwide Inpatient Sample (NIS), a nationally representative dataset of all admissions in the United States from 2005 to 2007. We analyzed the prevalence of angioplasty procedure for cerebral vasospasm at the national level. In-hospital mortality, discharge status, length of stay, and cost of hospitalization were compared between hospitals performing angioplasty with those not performing angioplasty in multivariable model, adjusted for patient's age, utilization of endovascular aneurysm obliteration, and disease severity. RESULTS: Of the 74,356 estimated patients with nontraumatic SAH, 47% (n = 35,172) were admitted to hospitals that perform angioplasty for cerebral vasospasm and only 1307 patients (3.8%) were treated with angioplasty for vasospasm. In multivariable analysis, after adjustment for patient and hospital characteristics, we found that patients admitted to hospitals performing angioplasty had higher rates of discharge to home without supervision (OR 1.3, 95% CI: 1.1-1.6). There was no difference in in-hospital mortality, length of stay, or cost of hospitalization. CONCLUSIONS: Our analysis suggests that the odds of a patient being discharged to home are better at hospitals performing angioplasty for cerebral vasospasm. Provision of angioplasty may be used as a surrogate marker of model of care in management of patients with SAH.
Authors: Joshua B Bederson; E Sander Connolly; H Hunt Batjer; Ralph G Dacey; Jacques E Dion; Michael N Diringer; John E Duldner; Robert E Harbaugh; Aman B Patel; Robert H Rosenwasser Journal: Stroke Date: 2009-01-22 Impact factor: 7.914
Authors: Alisa M Shea; Shelby D Reed; Lesley H Curtis; Michael J Alexander; John J Villani; Kevin A Schulman Journal: Neurosurgery Date: 2007-12 Impact factor: 4.654
Authors: Marike Zwienenberg-Lee; Jonathan Hartman; Nancy Rudisill; Lori Kennedy Madden; Karen Smith; Joseph Eskridge; David Newell; Bon Verweij; M Ross Bullock; Andrew Baker; William Coplin; Robert Mericle; Jian Dai; David Rocke; J Paul Muizelaar Journal: Stroke Date: 2008-04-17 Impact factor: 7.914
Authors: DeWitte T Cross; David L Tirschwell; Mary Ann Clark; Dan Tuden; Colin P Derdeyn; Christopher J Moran; Ralph G Dacey Journal: J Neurosurg Date: 2003-11 Impact factor: 5.115
Authors: Adnan I Qureshi; M Fareed K Suri; Abu Nasar; Jawad F Kirmani; Mustapha A Ezzeddine; Afshin A Divani; Wayne H Giles Journal: Stroke Date: 2007-05-24 Impact factor: 7.914
Authors: Mitchell F Berman; Robert A Solomon; Stephan A Mayer; S Claiborne Johnston; Pixie P Yung Journal: Stroke Date: 2003-08-07 Impact factor: 7.914
Authors: Rakesh Khatri; Muhammad Zeeshan Memon; Haralabos Zacharatos; Ather M Taqui; Mushtaq H Qureshi; Gabriela Vazquez; M Fareed K Suri; Gustavo J Rodriguez; Ramachandra P Tummala; Mustapha A Ezzeddine; Adnan I Qureshi Journal: Neurocrit Care Date: 2011-08 Impact factor: 3.210
Authors: Aditya S Pandey; Joseph J Gemmete; Thomas J Wilson; Neeraj Chaudhary; B Gregory Thompson; Lewis B Morgenstern; James F Burke Journal: Neurosurgery Date: 2015-09 Impact factor: 4.654
Authors: Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel Journal: Neurocrit Care Date: 2011-09 Impact factor: 3.210
Authors: Uma V Mahajan; Hammad A Khan; Xiaofei Zhou; Shaarada Srivatsa; Christina H Wright; Adam H Bates; Martha Sajatovic; Nicholas C Bambakidis Journal: Neurocrit Care Date: 2022-09-16 Impact factor: 3.532
Authors: Vishank A Shah; Syed Omar Kazmi; Rahul Damani; Alyssa Hartsell Harris; Samuel F Hohmann; Eusebia Calvillo; Jose I Suarez Journal: Front Neurol Date: 2022-06-16 Impact factor: 4.086
Authors: Hormuzdiyar H Dasenbrock; Robert F Rudy; William B Gormley; Kai U Frerichs; M Ali Aziz-Sultan; Rose Du Journal: Neurocrit Care Date: 2018-12 Impact factor: 3.210
Authors: Charles Hobson; John Dortch; Tezcan Ozrazgat Baslanti; Daniel R Layon; Alina Roche; Alison Rioux; Jeffrey S Harman; Brenda Fahy; Azra Bihorac Journal: PLoS One Date: 2014-08-20 Impact factor: 3.240
Authors: Juliette C Thompson; François-Xavier Chalet; Eric J Manalastas; Neil Hawkins; Grammati Sarri; Darren A Talbot Journal: Neurol Ther Date: 2022-04-20